Research advances over the past decades have in many cases transformed advanced cancer from a lethal diagnosis to a manageable chronic condition; in some cases, advanced cancers can even be cured.  These advances have been driven by fundamental research into the mechanisms which malignant transformation subverts the machinery of the cancer cell and impacts the tumor microenvironment.  Translational work guided by these basic discoveries has led to better strategies for cancer prevention, guided the creation of new targeted cancer therapies, and spurred the performance of clinical trials to assess efficacy of new therapeutic modalities.  The volume of publications on these topics is vast, and increasing, and the need for thoughtful analysis and synopsis is greater than ever.

The goal of Cancer & Metastasis Reviews is to highlight recent significant advances in basic, translational, and clinical research, emphasizing studies that have high impact for control of cancer, or have outstanding potential in this regard.  Topics that will be considered include:
 
Function of oncogenes and tumor suppressors
Regulation of cell death in cancer
Control of cell cycle and DNA repair in cancer
Inflammation and immune system defects related to carcinogenesis
Impact of the microbiome on carcinogenesis and therapeutic response
Changes in cell metabolism linked to transformation
Genetic and epigenetic changes during tumor formation, progression, metastasis, and response to treatment
Tumor microenvironment, pre-metastatic and metastatic niches, and tumor dormancy
Aging and cancer
Development of molecularly targeted cancer therapies, including cellular therapies and immunotherapies, and clinical trials of such agents
Biological and molecular factors related to cancer risk, cancer prevention, and cancer interception
Systems biology and computational biology technologies for identification and characterization of cancer targets
Technologies for early detection of new or recurrent tumors, and for monitoring response to treatment
Predictive and prognostic biomarkers for cancer therapy.
Cancer Disparities

Editors-in-Chief:
Kenneth V. Honn
Distinguished Professor of Pathology, Oncology and Chemistry
Wayne State University School of Medicine, Detroit, MI, USA
Avraham Raz
Paul Zuckerman Professor of Oncology and Pathology,
Barbara Ann Karmanos Cancer Institute
Wayne State University, School of Medicine, Detroit, MI, USA
Editorial Advisory Board:
Robin Anderson, Peter MacCallum Cancer Center, Australia 
Menashe Bar-Eli, UTMD Anderson Cancer Center, USA 
Ann F. Chambers, London Health Sciences Center, Canada; 
Michael Cher, Wayne State University School of Medicine, USA
David Cheresh, University of California, San Diego, USA 
Isaiah J. Fidler, UTMD Anderson Cancer Center, USA
Paul Fisher, Virginia Commonwealth, USA
Mary J.C. Hendrix, Children's Hospital of Chicago Research Center, USA 
Meenhard Herlyn, The Wistar Institute, USA 
Yusuf Hannun, Stony Brook University, USA
Mien-Chie Hung, University of Texas MD Anderson Cancer Center, USA
John T. Isaacs, The Johns Hopkins Oncology Center, USA 
Rakesh Kumar, Rajiv Gandhi Centre for Biotechnology, India
Lawrence J. Marnett, Vanderbilt University School of Medicine, USA 
Dipak Panigrahy, Harvard Medical School, USA
Richard Phipps, University of Rochester Medical Center, USA
Kenneth J. Pienta, Johns Hopkins University, USA 
Charles Serhan, Harvard Medical School, USA
Bonnie Sloane, Wayne State University School of Medicine, USA 
Saburo Sone, Tokushima University School of Medicine, Japan 
Joszef Timar, Semmelweis University, Hungary 
Danny Welch, Kansas University Cancer Center, USA


Founding Editors: 
Isaiah J. Fidler
Garth L. Nicolson
George Poste